Mei Ri Jing Ji Xin Wen·2025-05-30 12:06Market Overview - The market continued its upward trend, with the Shanghai Composite Index rising by 0.21% to close at 3387.57 points. The total trading volume in Shanghai, Shenzhen, and Beijing exceeded 1.2 trillion yuan, showing a slight increase compared to the previous day [1]. Company News - Domestic innovative drug company, 3SBio, announced a licensing agreement with Pfizer for its self-developed PD-1/VEGF bispecific antibody "SSGJ-707," granting Pfizer exclusive global rights outside of mainland China. This deal includes a non-refundable upfront payment of $1.25 billion and potential milestone payments up to $4.8 billion, bringing the total potential deal value to $6.05 billion, which exceeds 43 billion yuan at current exchange rates [1]. Investment Competition - The 60th edition of the simulated stock trading competition, hosted by the Daily Economic News App, is currently ongoing. Participants have shown interest in innovative drug concept stocks, with some achieving a 20% limit-up on stocks like Shuyou Shen [1]. Market Sentiment - Some participants believe that as long as the Shanghai Composite Index remains above the key support level of 3350 points, the upward trend is considered normal. The pressure level for the index is around 3420 points, and a successful breakthrough could lead to a major upward wave. Additionally, a potential interest rate cut by the Federal Reserve in the second half of the year could benefit global markets [10]. Sector Opportunities - Participants in the competition are optimistic about opportunities in sectors such as innovative drug exports, banking, and infrastructure assets like highways and water supply [10].